Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

Summary Background Treatment options are limited for patients infected by hepatitis C virus (HCV) with advanced liver disease. We assessed the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and advanced liver disease. Methods We did an open-label st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2016-06, Vol.16 (6), p.685-697
Hauptverfasser: Manns, Michael, Prof, Samuel, Didier, Prof, Gane, Edward J, Prof, Mutimer, David, Prof, McCaughan, Geoff, Prof, Buti, Maria, Prof, Prieto, MartÍn, MD, Calleja, José Luis, MD, Peck-Radosavljevic, Markus, Prof, Müllhaupt, Beat, Prof, Agarwal, Kosh, MD, Angus, Peter, Prof, Yoshida, Eric M, MD, Colombo, Massimo, Prof, Rizzetto, Mario, Prof, Dvory-Sobol, Hadas, PhD, Denning, Jill, MA, Arterburn, Sarah, MS, Pang, Phillip S, MD, Brainard, Diana, MD, McHutchison, John G, MD, Dufour, Jean-François, MD, Van Vlierberghe, Hans, Prof, van Hoek, Bart, Prof, Forns, Xavier, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!